Oral cavity and oropharyngeal squamous cell carcinoma - An update

CA Cancer Journal for Clinicians

Volumn 65, Issue 5, 2015, Pages 401-421

  Chi, Angela C ^a   Day, Terry A ^a   Neville, Brad W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

cancer; human papillomavirus; oral cavity; oropharynx; squamous cell carcinoma

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ANTIBIOTIC AGENT; ARSENIC; CHROMIUM; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NICKEL; PROTEIN P53; VIRUS DNA; WART VIRUS VACCINE;

ACCREDITATION; ADH1B GENE; ADH1B2 GENE; ADH1C GENE; ADH1C2 GENE; ADJUVANT CHEMORADIOTHERAPY; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALDH1 GENE; ALDH2 GENE; ALLELE; ARTICLE; BETEL QUID; BONE NECROSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANDIDA; CARCINOGENESIS; CDKN2A GENE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIET; DYSPHAGIA; EARLY DIAGNOSIS; ERYTHROPLASIA; FIBROSIS; FINE NEEDLE ASPIRATION BIOPSY; FRUIT; GENE; HERITABILITY; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; INCOME; LEUKOPLAKIA; LOWEST INCOME GROUP; MALOCCLUSION; MEDICAL EDUCATION; MEDICAL SERVICE; MICROSCOPY; MORBIDITY; MOUTH FLORA; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; NEISSERIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING EDUCATION; OCCUPATIONAL EXPOSURE; ORAL CAVITY SQUAMOUS CELL CARCINOMA; ORAL SURGERY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PALATAL OBTURATOR; PALATOPHARYNGEAL INCOMPETENCE; PALATOPLASTY; PHARYNX RECONSTRUCTION; PLANT LEAF; POLLUTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION CARE; RISK FACTOR; ROBOT ASSISTED SURGERY; SEX DIFFERENCE; SOCIOECONOMICS; SPEECH DISORDER; STREPTOCOCCUS; TH2 CELL; TOBACCO; TP53 GENE; TREND STUDY; TRISMUS; VEGETABLE; VISUAL SYSTEM EXAMINATION; WART VIRUS; XEROSTOMIA; CARCINOMA, SQUAMOUS CELL; HEALTH; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; TRENDS;

CARCINOMA, SQUAMOUS CELL; GLOBAL HEALTH; HUMANS; MORBIDITY; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS;

EID: 84941600162     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21293     Document Type: Article

References (211)

1. Neville BW, Day TA,. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002; 52: 195-215.
2. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2012 [based on the November 2014 SEER data submission, posted to the SEER website, April 2015]. Bethesda, MD: National Cancer Institute; 2015. seer.cancer.gov/csr/1975-2012/. Accessed June 2, 2015.
3. Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 version 1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. globocan.iarc.fr. Accessed June 2, 2015.
4. Ferlay J, Bray F, Steliarova-Foucher E, Forman D,. Cancer Incidence in Five Continents, CI5plus. IARC CancerBase No. 9. Lyon, France: International Agency for Research on Cancer; 2014. ci5.iarc.fr. Accessed June 2, 2015.
5. Steliarova-Foucher E, O'Callaghan M, Ferlay J, et al., European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012). European Network of Cancer Registries, International Agency for Research on Cancer. eco.iarc.fr. Accessed June 2, 2013.
6. Deschler DG, Richmon JD, Khariwala SS, Ferris RL, Wang MB,. The "new" head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014; 151: 375-380.
7. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
8. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al., Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013; 31: 4550-4559.
9. Forte T, Niu J, Lockwood GA, Bryant HE,. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control. 2012; 23: 1343-1348.
10. Blomberg M, Nielsen A, Munk C, Kjaer SK,. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer. 2011; 129: 733-741.
11. Monteiro LS, Antunes L, Bento MJ, Warnakulasuriya S,. Incidence rates and trends of lip, oral and oro-pharyngeal cancers in Portugal. J Oral Pathol Med. 2013; 42: 345-351.
12. Braakhuis BJ, Leemans CR, Visser O,. Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011. Oral Oncol. 2014; 50: 670-675.
13. Shin A, Jung YS, Jung KW, Kim K, Ryu J, Won YJ,. Trends of human papillomavirus-related head and neck cancers in Korea: National Cancer Registry data. Laryngoscope. 2013; 123: E30-E37.
14. Ariyawardana A, Johnson NW,. Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982-2008: overall good news but with rising rates in the oropharynx [serial online]. BMC Cancer. 2013; 13: 333.
15. Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R,. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012; 147: 74-78.
16. Choi SW, Moon EK, Park JY, et al., Trends in the incidence of and survival rates for oral cavity cancer in the Korean population. Oral Dis. 2014; 20: 773-779.
17. Takiar R, Nadayil D, Nandakumar A,. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev. 2010; 11: 1045-1049.
18. Yeole BB,. Trends in incidence of head and neck cancers in India. Asian Pac J Cancer Prev. 2007; 8: 607-612.
19. Gillison ML, Koch WM, Capone RB, et al., Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
20. Chaturvedi AK,. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012; 6 (suppl 1): S16-S24.
21. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
22. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26: 612-619.
23. Muller S, Pan Y, Li R, Chi AC,. Changing trends in oral squamous cell carcinoma with particular reference to young patients: 1971-2006. The Emory University experience. Head Neck Pathol. 2008; 2: 60-66.
24. Patel SC, Carpenter WR, Tyree S, et al., Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011; 29: 1488-1494.
25. Toporcov TN, Znaor A, Zhang ZF, et al., Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. Int J Epidemiol. 2015; 44: 169-185.
26. O'Regan EM, Toner ME, Finn SP, et al., p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum Pathol. 2008; 39: 452-458.
27. Tsimplaki E, Argyri E, Xesfyngi D, Daskalopoulou D, Stravopodis DJ, Panotopoulou E,. Prevalence and expression of human papillomavirus in 53 patients with oral tongue squamous cell carcinoma. Anticancer Res. 2014; 34: 1021-1025.
28. Poling JS, Ma XJ, Bui S, et al., Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue. Oral Oncol. 2014; 50: 306-310.
29. Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ,. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck. 2011; 33: 1622-1627.
30. El-Mofty SK, Lu DW,. Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2003; 27: 1463-1470.
31. Siebers TJ, Merkx MA, Slootweg PJ, Melchers WJ, van Cleef P, de Wilde PC,. No high-risk HPV detected in SCC of the oral tongue in the absolute absence of tobacco and alcohol-a case study of seven patients. Oral Maxillofac Surg. 2008; 12: 185-188.
32. Liang XH, Lewis J, Foote R, Smith D, Kademani D,. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg. 2008; 66: 1875-1880.
33. Kabeya M, Furuta R, Kawabata K, Takahashi S, Ishikawa Y,. Prevalence of human papillomavirus in mobile tongue cancer with particular reference to young patients. Cancer Sci. 2012; 103: 161-168.
34. Braakhuis BJ, Rietbergen MM, Buijze M, et al., TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients. Oral Dis. 2014; 20: 602-608.
35. Bragelmann J, Dagogo-Jack I, El Dinali M, et al., Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013; 49: 525-533.
36. Chang AM, Kim SW, Duvvuri U, et al., Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed. Oral Oncol. 2013; 49: 1077-1082.
37. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER∗Stat Database: Incidence-SEER 18 Registries Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2014 submission (2000-2012) [released April 2015, based on the November 2014 submission.]. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2014.
38. Surveillance Research Program, National Cancer Institute. SEER∗Stat software, version 8.2.1. Bethesda, MD: National Cancer Institute; 2013. seer.cancer.gov/seerstat. Accessed June 3, 2015.
39. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. List of Classifications by Cancer Site. monographs.iarc.fr/ENG/Classification/index.php. Accessed June 3, 2015.
40. World Health Organization (WHO). WHO Report on the Global Tobacco Epidemic 2013. who.int/tobacco/global-report/2013/en/. Accessed June 3, 2015.
41. Gandini S, Botteri E, Iodice S, et al., Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008; 122: 155-164.
42. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risk in Humans. Tobacco Smoke and Involuntary Smoking. Volume 83. Lyon, France: IARC Press; 2004.
43. Centers for Disease Control and Prevention. Consumption of cigarettes and combustible tobacco-United States, 2000-2011. MMWR Morb Mortal Wkly Rep. 2012; 61: 565-569.
44. Randi G, Scotti L, Bosetti C, et al., Pipe smoking and cancers of the upper digestive tract. Int J Cancer. 2007; 121: 2049-2051.
45. Rodu B, Jansson C,. Smokeless tobacco and oral cancer: a review of the risks and determinants. Crit Rev Oral Biol Med. 2004; 15: 252-263.
46. Luo J, Ye W, Zendehdel K, et al., Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet. 2007; 369: 2015-2020.
47. Weitkunat R, Sanders E, Lee PN,. Meta-analysis of the relation between European and American smokeless tobacco and oral cancer [serial online]. BMC Public Health. 2007; 7: 334.
48. Lee PN, Hamling J,. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America [serial online]. BMC Med. 2009; 7: 36.
49. Lee PN,. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol. 2011; 59: 197-214.
50. Nordenvall C, Nilsson PJ, Ye W, Andersson TM, Nyren O,. Tobacco use and cancer survival: a cohort study of 40,230 Swedish male construction workers with incident cancer. Int J Cancer. 2013; 132: 155-161.
51. Lee PN,. Health risks related to dual use of cigarettes and snus-a systematic review. Regul Toxicol Pharmacol. 2014; 69: 125-134.
52. Hamari AK, Toljamo TI, Kinnula VL, Nieminen PA,. Dual use of cigarettes and Swedish snuff (snus) among young adults in Northern Finland. Eur J Public Health. 2013; 23: 768-771.
53. International Agency for Research on Cancer (IARC). Section 2.2. Cancer of the oral cavity and pharynx. In: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, eds. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Alcohol Consumption and Ethylcarbamate. Volume 96. Lyon, France: IARC Press; 2010: 237-329.
54. Turati F, Garavello W, Tramacere I, et al., A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol Alcohol. 2013; 48: 107-118.
55. Chang JS, Straif K, Guha N,. The role of alcohol dehydrogenase genes in head and neck cancers: a systematic review and meta-analysis of ADH1B and ADH1C. Mutagenesis. 2012; 27: 275-286.
56. Tsai ST, Wong TY, Ou CY, et al., The interplay between alcohol consumption, oral hygiene, ALDH2 and ADH1B in the risk of head and neck cancer. Int J Cancer. 2014; 135: 2424-2436.
57. International Agency for Research on Cancer (IARC). Section 1.6. Chemical composition of alcoholic beverages, additives and contaminants. In: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, eds. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Alcohol Consumption and Ethylcarbamate. Volume 96. Lyon, France: IARC Press; 2010: 79-137.
58. Lachenmeier DW, Monakhova YB,. Short-term salivary acetaldehyde increase due to direct exposure to alcoholic beverages as an additional cancer risk factor beyond ethanol metabolism [serial online]. J Exp Clin Cancer Res. 2011; 30: 3.
59. Anantharaman D, Marron M, Lagiou P, et al., Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. Oral Oncol. 2011; 47: 725-731.
60. Hashibe M, Brennan P, Chuang SC, et al., Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18: 541-550.
61. Petti S, Mohd M, Scully C,. Revisiting the association between alcohol drinking and oral cancer in nonsmoking and betel quid non-chewing individuals. Cancer Epidemiol. 2012; 36: e1-e6.
62. Petti S,. Lifestyle risk factors for oral cancer. Oral Oncol. 2009; 45: 340-350.
63. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risk in Humans. Betel-Quid and Areca-Nut Chewing and Some Areca-Nut-Derived Nitrosamines. Volume 85. Lyon, France: IARC Press; 2004.
64. Guha N, Warnakulasuriya S, Vlaanderen J, Straif K,. Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. Int J Cancer. 2014; 135: 1433-1443.
65. Gupta B, Johnson NW,. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific [serial online]. PLoS One 9: e113385, 2014.
66. Merchant AT, Pitiphat W,. Total, direct, and indirect effects of paan on oral cancer. Cancer Causes Control. 2015; 26: 487-491.
67. Song H, Wan Y, Xu YY,. Betel quid chewing without tobacco: a meta-analysis of carcinogenic and precarcinogenic effects. Asia Pac J Public Health. 2015; 27: NP47-NP57.
68. Petti S, Masood M, Scully C,. The magnitude of tobacco smoking-betel quid chewing-alcohol drinking interaction effect on oral cancer in South-East Asia. A meta-analysis of observational studies [serial online]. PLoS One. 8: e78999, 2013.
69. Mirghani H, Amen F, Moreau F, Lacau St Guily J,. Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma? Oral Oncol. 2015; 51: 229-236.
70. de Martel C, Ferlay J, Franceschi S, et al., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-615.
71. Forman D, de Martel C, Lacey CJ, et al., Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 (suppl 5): F12-F23.
72. Ndiaye C, Mena M, Alemany L, et al., HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014; 15: 1319-1331.
73. Dalianis T,. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (review). Int J Oncol. 2014; 44: 1799-1805.
74. Benson E, Li R, Eisele D, Fakhry C,. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol. 2014; 50: 565-574.
75. Mehanna H, Beech T, Nicholson T, et al., Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2013; 35: 747-755.
76. Gillison ML, D'Souza G, Westra W, et al., Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100: 407-420.
77. Dahlstrom KR, Li G, Tortolero-Luna G, Wei Q, Sturgis EM,. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck. 2011; 33: 847-855.
78. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
79. D'Souza G, Zhang HH, D'Souza WD, Meyer RR, Gillison ML,. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol. 2010; 46: 100-104.
80. Hong AM, Martin A, Chatfield M, et al., Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. Int J Cancer. 2013; 132: 2748-2754.
81. Maxwell JH, Kumar B, Feng FY, et al., Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010; 16: 1226-1235.
82. Sood AJ, McIlwain W, O'Connell B, Nguyen S, Houlton JJ, Day T,. The association between T-stage and clinical nodal metastasis In HPV-positive oropharyngeal cancer. Am J Otolaryngol. 2014; 35: 463-468.
83. Begum S, Cao D, Gillison M, Zahurak M, Westra WH,. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005; 11: 5694-5699.
84. Califano J, van der Riet P, Westra W, et al., Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996; 56: 2488-2492.
85. Braakhuis BJ, Snijders PJ, Keune WJ, et al., Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004; 96: 998-1006.
86. Mroz EA, Baird AH, Michaud WA, Rocco JW,. COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res. 2008; 68: 6049-6053.
87. Herfs M, Vargas SO, Yamamoto Y, et al., A novel blueprint for "top down" differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J Pathol. 2013; 229: 460-468.
88. Lyford-Pike S, Peng S, Young GD, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73: 1733-1741.
89. Wang L, Ganly I,. The oral microbiome and oral cancer. Clin Lab Med. 2014; 34: 711-719.
90. Hooper SJ, Wilson MJ, Crean SJ,. Exploring the link between microorganisms and oral cancer: a systematic review of the literature. Head Neck. 2009; 31: 1228-1239.
91. Ahrens W, Pohlabeln H, Foraita R, et al., Oral health, dental care and mouthwash associated with upper aerodigestive tract cancer risk in Europe: the ARCAGE study. Oral Oncol. 2014; 50: 616-625.
92. Gondivkar SM, Gondivkar RS, Gadbail AR, Chole R, Mankar M, Yuwanati M,. Chronic periodontitis and the risk of head and neck squamous cell carcinoma: facts and figures. Exp Oncol. 2013; 35: 163-167.
93. Fitzpatrick SG, Katz J,. The association between periodontal disease and cancer: a review of the literature. J Dent. 2010; 38: 83-95.
94. Bravi F, Bosetti C, Filomeno M, et al., Foods, nutrients and the risk of oral and pharyngeal cancer. Br J Cancer. 2013; 109: 2904-2910.
95. Edefonti V, Hashibe M, Ambrogi F, et al., Nutrient-based dietary patterns and the risk of head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Ann Oncol. 2012; 23: 1869-1880.
96. Chuang SC, Jenab M, Heck JE, et al., Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. Cancer Causes Control. 2012; 23: 69-88.
97. Richie JP Jr, Kleinman W, Marina P, Abraham P, Wynder EL, Muscat JE,. Blood iron, glutathione, and micronutrient levels and the risk of oral cancer. Nutr Cancer. 2008; 60: 474-482.
98. Grimm M, Cetindis M, Biegner T, et al., Serum vitamin D levels of patients with oral squamous cell carcinoma (OSCC) and expression of vitamin D receptor in oral precancerous lesions and OSCC. Med Oral Pathol Oral Cir Bucal. 2015; 20: e188-e195.
99. Lipworth L, Rossi M, McLaughlin JK, et al., Dietary vitamin D and cancers of the oral cavity and esophagus. Ann Oncol. 2009; 20: 1576-1581.
100. Orell-Kotikangas H, Schwab U, Osterlund P, Saarilahti K, Makitie O, Makitie AA,. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck. 2012; 34: 1450-1455.
101. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370: 59-67.
102. van Leeuwen MT, Grulich AE, McDonald SP, et al., Immunosuppression and other risk factors for lip cancer after kidney transplantation. Cancer Epidemiol Biomarkers Prev. 2009; 18: 561-569.
103. Collett D, Mumford L, Banner NR, Neuberger J, Watson C,. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010; 10: 1889-1896.
104. Michaud DS, Langevin SM, Eliot M, et al., Allergies and risk of head and neck cancer. Cancer Causes Control. 2012; 23: 1317-1322.
105. Hsiao JR, Ou CY, Lo HI, et al., Allergies and risk of head and neck cancer: an original study plus meta-analysis [serial online]. PLoS One. 2013; 8: e55138.
106. Chiang CT, Lian Ie B, Su CC, Tsai KY, Lin YP, Chang TK,. Spatiotemporal trends in oral cancer mortality and potential risks associated with heavy metal content in Taiwan soil. Int J Environ Res Public Health. 2010; 7: 3916-3928.
107. Su CC, Tsai KY, Hsu YY, Lin YY, Lian Ie B,. Chronic exposure to heavy metals and risk of oral cancer in Taiwanese males. Oral Oncol. 2010; 46: 586-590.
108. Lin WC, Lin YP, Wang YC, Chang TK, Chiang LC,. Assessing and mapping spatial associations among oral cancer mortality rates, concentrations of heavy metals in soil, and land use types based on multiple scale data. Int J Environ Res Public Health. 2014; 11: 2148-2168.
109. Riechelmann H,. [Occupational exposure and cancer of the oral cavity and pharynx]. Laryngorhinootologie. 2002; 81: 573-579.
110. Masserot C, Peffault de Latour R, Rocha V, et al., Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer. 2008; 113: 3315-3322.
111. Wong WM, Parvathaneni U, Jewell PD, et al., Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: a case report and review of the literature. Head Neck. 2013; 35: E292-E298.
112. Alter BP, Giri N, Savage SA, Quint WG, de Koning MN, Schiffman M,. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int J Cancer. 2013; 133: 1513-1515.
113. Ray JG, Swain N, Ghosh R, Richa, Pattanayak Mohanty S,. Dyskeratosis congenita with malignant transformation [serial online]. BMJ Case Rep. 2011; 2011; bcr03202848.
114. Berkower AS, Biller HF,. Head and neck cancer associated with Bloom's syndrome. Laryngoscope. 1988; 98: 746-748.
115. Warnakulasuriya S, Johnson NW, van der Waal I,. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36: 575-580.
116. Napier SS, Speight PM,. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008; 37: 1-10.
117. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH,. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978; 46: 518-539.
118. Chi AC,. Epithelial pathology. In:, Neville BW, Damm DD, Allen CM, Bouquot JE, eds. Oral and Maxillofacial Pathology. 3rd ed. St. Louis, MO: Elsevier; 2009: 362-452.
119. Waldron CA, Shafer WG,. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 1975; 36: 1386-1392.
120. Silverman S Jr, Gorsky M, Lozada F,. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984; 53: 563-568.
121. Lind PO,. Malignant transformation in oral leukoplakia. Scand J Dent Res. 1987; 95: 449-455.
122. Bouquot JE, Gorlin RJ,. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986; 61: 373-381.
123. Liu W, Wang YF, Zhou HW, Shi P, Zhou ZT, Tang GY,. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients [serial online]. BMC Cancer. 2010; 10: 685.
124. Brouns E, Baart J, Karagozoglu K, Aartman I, Bloemena E, van der Waal I,. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis. 2014; 20: e19-e24.
125. Ho MW, Risk JM, Woolgar JA, et al., The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral Oncol. 2012; 48: 969-976.
126. Liu W, Shi LJ, Wu L, et al., Oral cancer development in patients with leukoplakia-clinicopathological factors affecting outcome [serial online]. PLoS One. 2012; 7: e34773.
127. van der Waal I,. Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Pathol Oral Cir Bucal. 2014; 19: e386-e390.
128. Hansen LS, Olson JA, Silverman S, Jr,. Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol. 1985; 60: 285-298.
129. Cabay RJ, Morton TH Jr, Epstein JB,. Proliferative verrucous leukoplakia and its progression to oral carcinoma: a review of the literature. J Oral Pathol Med. 2007; 36: 255-261.
130. Bagan JV, Jimenez-Soriano Y, Diaz-Fernandez JM, et al., Malignant transformation of proliferative verrucous leukoplakia to oral squamous cell carcinoma: a series of 55 cases. Oral Oncol. 2011; 47: 732-735.
131. Silverman S Jr, Gorsky M,. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 84: 154-157.
132. Reichart PA, Philipsen HP,. Oral erythroplakia-a review. Oral Oncol. 2005; 41: 551-561.
133. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015. cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed June 3, 2015.
134. Krishna Rao SV, Mejia G, Roberts-Thomson K, Logan R,. Epidemiology of oral cancer in Asia in the past decade-an update (2000-2012). Asian Pac J Cancer Prev. 2013; 14: 5567-5577.
135. Su CC, Yang HF, Huang SJ, Lian Ie B,. Distinctive features of oral cancer in Changhua County: high incidence, buccal mucosa preponderance, and a close relation to betel quid chewing habit. J Formos Med Assoc. 2007; 106: 225-233.
136. Reichart PA, Nguyen XH,. Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med. 2008; 37: 511-514.
137. McIlwain WR, Sood AJ, Nguyen SA, Day TA,. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014; 140: 441-447.
138. Lewis JS Jr, Khan RA, Masand RP, et al., Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma-prospective cohort and interobserver variability study. Histopathology. 2012; 60: 427-436.
139. Bishop JA, Lewis JS Jr, Rocco JW, Faquin WC,. HPV-related squamous cell carcinoma of the head and neck: an update on testing in routine pathology practice [published online ahead of print February 4, 2015]. Semin Diagn Pathol. doi: 10.1053/j.semdp.2015.02.013.
140. College of American Pathologists protocol for the examination of specimens from patients with carcinomas of the pharynx. cap.org/apps/docs/committees/cancer/cancer-protocols/2012/Pharynx-12protocol.pdf. Accessed June 2, 2015.
141. El-Naggar AK, Westra WH,. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012; 34: 459-461.
142. Rumboldt Z, Gordon L, Gordon L, Bonsall R, Ackermann S,. Imaging in head and neck cancer. Curr Treat Options Oncol. 2006; 7: 23-34.
143. Law CP, Chandra RV, Hoang JK, Phal PM,. Imaging the oral cavity: key concepts for the radiologist. Br J Radiol. 2011; 84: 944-957.
144. Arya S, Chaukar D, Pai P,. Imaging in oral cancers. Indian J Radiol Imaging. 2012; 22: 195-208.
145. Yesuratnam A, Wiesenfeld D, Tsui A, et al., Preoperative evaluation of oral tongue squamous cell carcinoma with intraoral ultrasound and magnetic resonance imaging-comparison with histopathological tumour thickness and accuracy in guiding patient management. Int J Oral Maxillofac Surg. 2014; 43: 787-794.
146. Goldenberg D, Begum S, Westra WH, et al., Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck. 2008; 30: 898-903.
147. Mydlarz WK, Liu J, Blanco R, Fakhry C,. Transcervical ultrasound identifies primary tumor site of unknown primary head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014; 151: 1090-1092.
148. Fakhry C, Agrawal N, Califano J, et al., The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncol. 2014; 50: 640-645.
149. Zhang MQ, El-Mofty SK, Davila RM,. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer. 2008; 114: 118-123.
150. Holmes BJ, Westra WH,. The expanding role of cytopathology in the diagnosis of HPV-related squamous cell carcinoma of the head and neck. Diagn Cytopathol. 2014; 42: 85-93.
151. Porceddu SV, Pryor DI, Burmeister E, et al., Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011; 33: 1675-1682.
152. Andrade RS, Heron DE, Degirmenci B, et al., Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006; 65: 1315-1322.
153. Roman BR, Goldenberg D, Givi B,; Education Committee of American Head and Neck Society (AHNS). Guideline recommended follow-up and surveillance of head and neck cancer survivors [published online ahead of print April 27, 2015]. Head Neck. doi: 10.1002/hed.24100.
154. Rabalais AG, Walvekar R, Nuss D, et al., Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope. 2009; 119: 1120-1124.
155. Ryan WR, Fee WE Jr, Le QT, Pinto HA,. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005; 115: 645-650.
156. Leung AS, Rath TJ, Hughes MA, Kim S, Branstetter BF 4th,. Optimal timing of first post-treatment FDG-PET/CT in head and neck squamous cell carcinoma [published online ahead of print April 27, 2015]. Head Neck. doi: 10.1002/hed.24112.
157. Isles MG, McConkey C, Mehanna HM,. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008; 33: 210-222.
158. Ho AS, Tsao GJ, Chen FW, et al., Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013; 119: 1349-1356.
159. Shah K, Te Marvelde L, Collins M, et al., Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. Oral Oncol. 2015; 51: 529-535.
160. Gupta T, Master Z, Kannan S, et al., Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011; 38: 2083-2095.
161. Bar-Ad V, Shi W, Tuluc M, et al., FDG-PET, a complementary modality to computed-tomography in radiotherapy target volume delineation for head and neck cancer [serial online]. J Nucl Med Radiat Ther. 2012; 1: 3.
162. American Joint Committee on Cancer (AJCC). Lip and oral cavity. In:, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010: 29-40.
163. American Joint Committee on Cancer (AJCC). Pharynx. In:, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010: 41-56.
164. Huang SH, Xu W, Waldron J, et al., Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015; 33: 836-845.
165. Brizel DM,. Different strokes for different folks: new paradigms for staging oropharynx cancer. J Clin Oncol. 2015; 33: 817-818.
166. Spector ME, Gallagher KK, Bellile E, et al., Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2014; 36: 1233-1240.
167. Duffy SA, Ronis DL, McLean S, et al., Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol. 2009; 27: 1969-1975.
168. Gillison ML, Zhang Q, Jordan R, et al., Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012; 30: 2102-2111.
169. Granata R, Miceli R, Orlandi E, et al., Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol. 2012; 23: 1832-1837.
170. Rietbergen MM, Witte BI, Velazquez ER, et al., Different prognostic models for different patient populations: validation of a new prognostic model for patients with oropharyngeal cancer in Western Europe. Br J Cancer. 2015; 112: 1733-1736.
171. Huang SH, Waldron JN, Milosevic M, et al., Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015; 121: 545-555.
172. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW,. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013; 119: 3034-3042.
173. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW,. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas [serial online]. PLoS Med. 2015; 12: e1001786.
174. National Comprehensive Care Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers, Version 2.2014. nccn.org/professionals/physician-gls/f-guidelines.asp#head-and-neck. Accessed June 3, 2015.
175. Bernier J, Domenge C, Ozsahin M, et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
176. Cooper JS, Pajak TF, Forastiere AA, et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
177. Monroe MM, Gross ND,. Evidence-based practice: management of the clinical node-negative neck in early-stage oral cavity squamous cell carcinoma. Otolaryngol Clin North Am. 2012; 45: 1181-1193.
178. Jerjes W, Upile T, Petrie A, et al., Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients [serial online]. Head Neck Oncol. 2010; 2: 9.
179. Civantos FJ, Zitsch RP, Schuller DE, et al., Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010; 28: 1395-1400.
180. Govers TM, Hannink G, Merkx MA, Takes RP, Rovers MM,. Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis. Oral Oncol. 2013; 49: 726-732.
181. Chaturvedi P, Datta S, Arya S, et al., Prospective study of ultrasound-guided fine-needle aspiration cytology and sentinel node biopsy in the staging of clinically negative T1 and T2 oral cancer [published online ahead of print May 31, 2014]. Head Neck. doi: 10.1002/hed.23787.
182. Flach GB, Bloemena E, Klop WM, et al., Sentinel lymph node biopsy in clinically N0 T1-T2 staged oral cancer: the Dutch multicenter trial. Oral Oncol. 2014; 50: 1020-1024.
183. Den Toom IJ, Heuveling DA, Flach GB, et al., Sentinel node biopsy for early-stage oral cavity cancer: the VU University Medical Center experience. Head Neck. 2015; 37: 573-578.
184. Melkane AE, Mamelle G, Wycisk G, et al., Sentinel node biopsy in early oral squamous cell carcinomas: a 10-year experience. Laryngoscope. 2012; 122: 1782-1788.
185. Expert Panel on Radiation Oncology-Head, Neck Cancer, Salama JK, Saba N, et al., ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncol. 2011; 47: 554-559.
186. de Almeida JR, Moskowitz AJ, Miles BA, et al., Transoral robotic surgery is cost-effective compared with (chemo)radiotherapy for early T-classification oropharyngeal carcinoma: a cost-utility analysis [published online ahead of print December 9, 2014]. Head Neck. doi: 10.1002/hed.23930.
187. More YI, Tsue TT, Girod DA, et al., Functional swallowing outcomes following transoral robotic surgery vs primary chemoradiotherapy in patients with advanced-stage oropharynx and supraglottis cancers. JAMA Otolaryngol Head Neck Surg. 2013; 139: 43-48.
188. Lin BM, Wang H, D'Souza G, et al., Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer. 2013; 119: 3462-3471.
189. Rietbergen MM, Braakhuis BJ, Moukhtari N, et al., No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors. J Oral Pathol Med. 2014; 43: 137-142.
190. Jain KS, Sikora AG, Baxi SS, Morris LG,. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer. 2013; 119: 1832-1837.
191. Epstein JB, Thariat J, Bensadoun RJ, et al., Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012; 62: 400-422.
192. Turner L, Mupparapu M, Akintoye SO,. Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner. Quintessence Int. 2013; 44: 267-279.
193. Hutcheson KA, Lewin JS,. Functional assessment and rehabilitation: how to maximize outcomes. Otolaryngol Clin North Am. 2013; 46: 657-670.
194. Guijarro-Martinez R, Gellrich NC, Witte J, et al., Optimization of the interface between radiology, surgery, radiotherapy, and pathology in head and neck tumor surgery: a navigation-assisted multidisciplinary network. Int J Oral Maxillofac Surg. 2014; 43: 156-162.
195. Haddad R, Annino D, Tishler RB,. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008; 52: 1-17, vii.
196. Beadle BM, Liao KP, Chambers MS, et al., Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: a SEER-Medicare analysis. Head Neck. 2013; 35: 1599-1605.
197. Dysphagia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology;, Raber-Durlacher JE, Brennan MT, et al., Swallowing dysfunction in cancer patients. Support Care Cancer. 2012; 20: 433-443.
198. National Cancer Institute. PDQ® Cancer Information Summaries. Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute; 2015. cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/healthprofessional. Accessed June 4, 2015.
199. Niewald M, Fleckenstein J, Mang K, Holtmann H, Spitzer WJ, Rube C,. Dental status, dental rehabilitation procedures, demographic and oncological data as potential risk factors for infected osteoradionecrosis of the lower jaw after radiotherapy for oral neoplasms: a retrospective evaluation [serial online]. Radiat Oncol. 2013; 8: 227.
200. Bensadoun RJ, Riesenbeck D, Lockhart PB, et al., A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer. 2010; 18: 1033-1038.
201. Hanasono MM, Matros E, Disa JJ,. Important aspects of head and neck reconstruction. Plast Reconstr Surg. 2014; 134: 968e-980e.
202. Patel SA, Chang EI,. Principles and practice of reconstructive surgery for head and neck cancer. Surg Oncol Clin North Am. 2015; 24: 473-489.
203. Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH,. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2015; 91: 925-933.
204. Hunter KU, Schipper M, Feng FY, et al., Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013; 85: 935-940.
205. Francis DO, Weymuller EA Jr, Parvathaneni U, Merati AL, Yueh B,. Dysphagia, stricture, and pneumonia in head and neck cancer patients: does treatment modality matter? Ann Otol Rhinol Laryngol. 2010; 119: 391-397.
206. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59: 630-632.
207. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59: 626-629.
208. Herrero R, Quint W, Hildesheim A, et al., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica [serial online]. PLoS One. 2013; 8: e68329.
209. Osazuwa-Peters N,. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States-do we need a broader vaccine policy? Vaccine. 2013; 31: 5500-5505.
210. Steinau M, Saraiya M, Goodman MT, et al., Human papillomavirus prevalence in oropharyngeal cancer cells before vaccine introduction, United States. Emerg Infect Dis. 2014; 20: 822-828.
211. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S,. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014; 168: 76-82.